Additive endocrine therapy for advanced breast cancer – back to the future

Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status

(2009) P.E. Lønning et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)

(2008) Jørn Andersen et al.   ACTA ONCOLOGICA

Estrogen Receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications

(2008) Maj-Lis M. Talman et al.   ACTA ONCOLOGICA

Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels

(2008) J. Geisler et al.   CLINICAL CANCER RESEARCH

Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?

(2008) P.E. Lønning   EUROPEAN JOURNAL OF CANCER

The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer—Survival or Death?

(2008) V. Craig Jordan   JOURNAL OF CLINICAL ONCOLOGY

Expression level of enzymes related to in situ estrogen synthesis and clinicopathological parameters in breast cancer patients

(2008) Masayo Suzuki et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY